#Ireland #Dublin #Theravance Biopharma #YUPELRI #Ampreloxetine

Theravance Biopharma to Present at the Oppenheimer Healthcare Conference

On February 12, 2025, Theravance Biopharma, Inc. (NASDAQ: TBPH) is scheduled to make a significant appearance at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. This highly anticipated event will begin at 12:00 PM EST (9:00 AM PST/5:00 PM GMT) and offers an excellent platform for the company to showcase its cutting-edge developments and innovations in the pharmaceutical field.

The conference is not just a routine gathering; it represents a crucial opportunity for investors, partners, and health care enthusiasts to gain insights into the latest advancements from leading companies in the life sciences sector. Theravance Biopharma encourages interested parties to join via webcast, which will be made accessible through their official website, specifically in the ‘Investors’ section under ‘Events and Presentations.’ The company has also committed to archiving this presentation for 30 days, ensuring that stakeholders can revisit it at their convenience.

Company Overview

Theravance Biopharma is committed to making a tangible difference in the lives of individuals through its innovative medicines. The company's cornerstone product, YUPELRI® (revefenacin) inhalation solution, is already FDA-approved for the long-term management of chronic obstructive pulmonary disease (COPD), reflecting its dedication to addressing critical health challenges.

Additionally, Theravance is advancing Ampreloxetine, a once-daily norepinephrine reuptake inhibitor currently in development for treating symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy (MSA). This pioneering therapy holds promise as a potential first-in-class treatment that targets several debilitating symptoms of MSA, exemplifying Theravance's commitment to developing therapies that improve patient outcomes.

What to Expect

During the Oppenheimer Conference, Theravance Biopharma is expected to discuss a variety of topics, including its current product offerings, ongoing clinical trials, future pipeline projects, and overall corporate strategy. Executives and research directors from the company will likely offer a comprehensive overview of both their short- and long-term goals in the pharmaceutical sector. Investors will gain valuable insights into how Theravance Biopharma plans to expand its market presence, drive shareholder value, and further its mission of improving health outcomes for patients.

Accessing the Conference

Those who wish to follow Theravance Biopharma's presentation at the Oppenheimer Conference can do so through the investor relations section of their website. Visiting Theravance's online platform will provide all the necessary details for tuning into the conference as well as complete investor information.

In a continually evolving healthcare landscape, events like the Oppenheimer Conference provide essential networking and learning opportunities. Investors and healthcare professionals are encouraged not to miss Theravance Biopharma's presentation as it showcases innovations and strategies aimed at reshaping the future of therapeutic solutions. This is particularly important as the company navigates its path in developing impactful medications that cater to unmet medical needs.

As the February 12 date approaches, anticipation grows surrounding what investors and interested parties will learn from Theravance Biopharma.

For further information about Theravance Biopharma, visit their website at www.theravance.com. All trademarks mentioned within this article are registered trademarks of their respective owners.